Gout Medication Krystexxa Given Intravenously
August 19, 2011 by Alex.
In 2010, the FDA approved the first and only gout medication to treat adults with chronic and severe gouty arthritis that didn't respond to existing gout drugs. The intravenous medication, Krystexxa (pegloticase), is derived from an animal hormone. The pegloticase mechanism of action is different than that of other gout medications - it converts uric acid to a nontoxic byproduct that is easily excreted in the urine.
Krystexxa is given as an intravenous infusion over at least two hours every two weeks. The FDA has warned that patients should be given a corticosteroid and antihistamine before infusions because of a high risk of allergic reaction. Other common side effects of Krystexxa are gout flare ups, nausea and vomiting, chest pain, constipation, nasal irritation and bruising at the injection site.
Despite these Krystexxa side effects, the FDA believes pegloticase is an important option for the 3% of gout patients that don't benefit from other gout medications such as prescription colchicine, allopurinol and febuxostat. Approximately 3 million Americans suffer from gouty arthritis.
Krystexxa was not studied in patients with congestive heart failure, and the FDA advises it should be used with caution in patients with the condition. Krystexxa is manufactured by Savient Pharmaceuticals, an American company based in New Jersey. For more information on the gout medication, visit krystexxa.com.
Filed under: Gout Medications.
Tags: colchicine, gout medication, krystexxa, pegloticase, gout drug, krystexxa side effects, prescription colchicine, gouty arthritis .
Leave your comment: